TY - JOUR
T1 - Monthly changes in serum levels of S100B protein as a predictor of metastasis development in high-risk melanoma patients
AU - Ertekin, S. S.
AU - Podlipnik, S.
AU - Ribero, S.
AU - Molina, R.
AU - Rios, J.
AU - Carrera, C.
AU - Malvehy, J.
AU - Puig, S.
N1 - Funding Information:
Funding source The study in the Melanoma Unit, Hospital Cl?nic, Barcelona, was supported in part by grants from Fondo de Investigaciones Sanitarias P.I. 12/00840, PI15/00956 and 15/00716 Spain; by the CIBER de Enfermedades Raras of the Instituto de Salud Carlos III, Spain, co-funded by ?Fondo Europeo de Desarrollo Regional (FEDER). Uni?n Europea. Una manera de hacer Europa?; by the AGAUR 2009 SGR 1337 and AGAUR 2014_SGR_603 of the Catalan Government, Spain; by a grant from ?Fundaci? La Marat? de TV3, 201331-30?, Catalonia, Spain; by the European Commission under the 6th Framework Programme, Contract n?: LSHC-CT-2006-018702 (GenoMEL); by CERCA Programme/Generalitat de Catalunya and by a Research Grant from Asociaci?n Espa?ola Contra el C?ncer. CERCA Programme/Generalitat de Catalunya. Thanks to our patients and their families who are the main reason for our studies; to nurses from the Melanoma Unit of Hospital Cl?nic of Barcelona, Daniel Gabriel, Pablo Iglesias and Maria E Moliner for helping to collect patient data, to Paul Hetherington for help with English editing and correction of the manuscript in English and Marc Combalia for his help with the online application.
Publisher Copyright:
© 2020 European Academy of Dermatology and Venereology
Copyright:
Copyright 2020 Elsevier B.V., All rights reserved.
PY - 2020/7/1
Y1 - 2020/7/1
N2 - Background: The role of S100B protein in detecting early melanoma relapses is controversial, since most metastasis occur within normal values of S100B. Objective: The aim of this study was to assess the performance of S100B in detecting early disease progression in high-risk melanoma patients. Methods: Retrospective cohort study including patients with an initial diagnosis of stage IIB, IIC and III melanoma between January 2003 and July 2013. All patients were followed up in accordance with an intensive protocol based on imaging studies and serum S100B levels every 3–6 months. We compared two methods to evaluate changes in S100B. The classic method referring to a single determination of S100B above the cut-off level at the time of metastasis, which was evaluated in all patients. And a new method based on monthly changes of S100, which was used in the setting of patients with S100B levels within the normal range. Results: Overall, 289 of patients were followed up for 44 months (IQR 17–73) and 45% developed metastases. During the study period, 129 patients relapsed of which 46 (35.7%) present elevated values of S100B at the time of relapse. The classic method had a sensitivity and specificity of S100B protein of 35.7% and 92.5%, respectively. Furthermore, for the patients that relapsed with normal values of S100B, the new method was applied and showed a sensitivity and specificity of 41.1% and 92.4%, respectively, allowing to detect additional relapses that were missing by the classic method. Conclusion: During follow-up of high-risk melanoma patients, rising serum S100B values within the normal range can be an important clue to disease progression.
AB - Background: The role of S100B protein in detecting early melanoma relapses is controversial, since most metastasis occur within normal values of S100B. Objective: The aim of this study was to assess the performance of S100B in detecting early disease progression in high-risk melanoma patients. Methods: Retrospective cohort study including patients with an initial diagnosis of stage IIB, IIC and III melanoma between January 2003 and July 2013. All patients were followed up in accordance with an intensive protocol based on imaging studies and serum S100B levels every 3–6 months. We compared two methods to evaluate changes in S100B. The classic method referring to a single determination of S100B above the cut-off level at the time of metastasis, which was evaluated in all patients. And a new method based on monthly changes of S100, which was used in the setting of patients with S100B levels within the normal range. Results: Overall, 289 of patients were followed up for 44 months (IQR 17–73) and 45% developed metastases. During the study period, 129 patients relapsed of which 46 (35.7%) present elevated values of S100B at the time of relapse. The classic method had a sensitivity and specificity of S100B protein of 35.7% and 92.5%, respectively. Furthermore, for the patients that relapsed with normal values of S100B, the new method was applied and showed a sensitivity and specificity of 41.1% and 92.4%, respectively, allowing to detect additional relapses that were missing by the classic method. Conclusion: During follow-up of high-risk melanoma patients, rising serum S100B values within the normal range can be an important clue to disease progression.
UR - http://www.scopus.com/inward/record.url?scp=85088120327&partnerID=8YFLogxK
U2 - 10.1111/JDV.16212
DO - 10.1111/JDV.16212
M3 - Article
C2 - 31967695
VL - 34
SP - 1482
EP - 1488
IS - 7
ER -
